Biotech startups that raised Series C
Updated 9 Nov 2026
Not sure about the data?
Download a free 25-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Microbiotica | Cambridge | Series C | $47.9M | 2026-10-16 |
| BigHat Biosciences | San Mateo | Series C | $75.0M | 2026-09-24 |
| Basecamp Research | London | Series C | $140.0M | 2026-09-23 |
| QL Biopharma | Beijing | Series C | $44.7M | 2026-09-14 |
| ImmunoPhotonics | St Louis | Series C | $10.1M | 2026-09-01 |
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Bridge to Life | Northbrook | Series C | $110.0M | 2026-08-12 |
| Ratio Therapeutics | Boston | Series C | $70.0M | 2026-07-31 |
8 rows of the CSV in 5 of its 15 columns.
- The 700 biotech startups that raised Series C have raised $55.2B in total.
- 72 of them closed their most recent round in the last 12 months, $4.4B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Hexagon Bio's $62.0M Series C on 23 October 2026.
- OrbiMed is an investor in 12 of them, more than any other fund.
- Health care is the most common other sector, with 621 companies (89%).
- 4% were founded in 2020 or later; the median founding year is 2012.
- The most common team size is 11 to 50 employees (43% of companies with a recorded size).
- 4 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 9 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 700| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Cambridge | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| ImmunoPhotonics | ImmunoPhotonics is a biotechnology company that develops cancer immunotherapies to stimulate immune responses against tumors. | Biotech | St Louis | Series C | $10.1M | 2026-09-01 | $42.0M | TCA Venture Group, Cultivation Capital, Arch Grants +1 | 11 to 50 | 2012 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| Diyingjia Technology | Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. | Artificial intelligence | Beijing | Series C | $3.0M | 2026-07-28 | $32.3M | IDG Capital, Legend Capital, Microsoft Accelerator | 11 to 50 | 2017 |
| Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
| Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Automata | Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. | Artificial intelligence | London | Series C | $45.0M | 2026-06-25 | $144.8M | Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 | 101 to 250 | 2015 |
| Cellanome | Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. | Biotech | Redwood City | Series C | $75.9M | 2026-06-18 | $289.6M | Premji Invest, Synetro Group | 51 to 100 | 2020 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| YolTech Therapeutics | YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. | Biotech | Minhang | Series C | $73.8M | 2026-05-29 | $144.9M | K2VC, UnityVC, Decheng Capital +1 | 11 to 50 | 2021 |
| Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Boston | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| Brainomix | Brainomix creates AI-powered imaging biomarkers that support precision medicine treatment decisions. | Artificial intelligence | Oxford | Series C | $6.5M | 2026-02-24 | $60.2M | Innovate UK, Parkwalk Advisors, Boehringer Ingelheim Venture Fund +1 | 51 to 100 | 2010 |
| Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| Colossal Biosciences Unicorn | Colossal Biosciences uses gene editing technology to pursue de-extinction of species. | Biotech | Austin | Series C | $60.0M | 2026-02-03 | $628.1M | Boost VC, Capital Factory, Climate Capital | 101 to 250 | 2021 |
| Nuclera | Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. | Biotech | Cambridge | Series C | $12.0M | 2026-01-13 | $157.8M | Innovate UK, Verve Ventures, Amadeus Capital Partners +2 | 101 to 250 | 2013 |
| Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge | Series C | $50.0M | 2026-01-09 | $225.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| Beacon Therapeutics | Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. | Biotech | Alachua | Series C | $75.0M | 2026-01-08 | $365.1M | Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 | 101 to 250 | 2023 |
Table 1. Biotech startups that raised Series C: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 9 November 2026. Base: 700.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| 3 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 4 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 5 | DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| 6 | Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
| 7 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 8 | Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| 9 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 10 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
Table 2. Biotech startups that raised Series C: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 9 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed | Private equity firm | new-york-new-york | 12 | 2% | 3 | Triveni Bio, Terremoto Biosciences, Aspen Neuroscience |
| 2 | RA Capital Management | Startup incubator | Boston | 11 | 2% | 2 | ADCendo, Terrestrial Bio |
| 3 | Bristol-Myers Squibb | Venture capital firm | new-york-new-york | 8 | 1% | 2 | BigHat Biosciences, Ratio Therapeutics |
| 4 | Khosla Ventures | Venture capital firm | Menlo Park | 7 | 1% | 2 | Prellis Biologics, Loyal |
| 5 | National Science Foundation | Entrepreneurship program | Alexandria | 7 | 1% | 1 | Culture Biosciences |
| 6 | KfW | Government investment office | Frankfurt | 7 | 1% | ||
| 7 | Novo Holdings | Corporate venture arm | Hellerup | 6 | 1% | 2 | Terremoto Biosciences, ADCendo |
| 8 | Alexandria Venture Investments | Venture capital firm | Pasadena | 5 | 1% | 2 | Triveni Bio, Aspen Neuroscience |
| 9 | Cormorant Asset Management | Hedge fund | Boston | 5 | 1% | 1 | Triveni Bio |
| 10 | Invus | Private equity firm | new-york-new-york | 5 | 1% | 1 | Triveni Bio |
| 11 | Decheng Capital | Venture capital firm | Menlo Park | 5 | 1% | 1 | YolTech Therapeutics |
| 12 | Y Combinator | Startup accelerator | Mountain View | 5 | 1% | 1 | Culture Biosciences |
| 13 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn | 5 | 1% | ||
| 14 | Temasek | Private equity firm | Singapore | 5 | 1% | ||
| 15 | Alumni Ventures | Angel group | Manchester | 5 | 1% |
Table 3. Biotech startups that raised Series C: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 9 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 621 | 89% | $50.8B |
| Software | 67 | 10% | $8.0B |
| Artificial intelligence | 36 | 5% | $5.4B |
| Hardware | 27 | 4% | $2.0B |
| Fintech | 7 | 1% | $543.0M |
| Energy | 6 | 1% | $245.8M |
| Education | 2 | 0% | $81.2M |
| Cybersecurity | 1 | 0% |
Table 4. Biotech startups that raised Series C by sector. Source: FundingWatcher. Data as of 9 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 700 | 100% | $28.5M |
Table 5. Biotech startups that raised Series C by stage of the most recent round. Source: FundingWatcher. Data as of 9 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 337 | 48% |
| China | 160 | 23% |
| United Kingdom | 39 | 6% |
| South Korea | 34 | 5% |
| Switzerland | 20 | 3% |
| Japan | 15 | 2% |
| Germany | 15 | 2% |
| Israel | 15 | 2% |
| Canada | 12 | 2% |
| France | 11 | 2% |
| Denmark | 5 | 1% |
| The Netherlands | 5 | 1% |
Table 6. Biotech startups that raised Series C by headquarters country. Source: FundingWatcher. Data as of 9 November 2026.
Cities
Table 7. Biotech startups that raised Series C by headquarters city. Source: FundingWatcher. Data as of 9 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 4 | 6% | $444.9M |
| September 2026 | 6 | 8% | $432.9M |
| August 2026 | 4 | 6% | $267.1M |
| July 2026 | 13 | 18% | $823.0M |
| June 2026 | 8 | 11% | $429.8M |
| May 2026 | 5 | 7% | $149.2M |
| April 2026 | 5 | 7% | $340.7M |
| March 2026 | 7 | 10% | $329.8M |
| February 2026 | 5 | 7% | $231.5M |
| January 2026 | 6 | 8% | $468.0M |
| December 2025 | 5 | 7% | $236.0M |
| November 2025 | 4 | 6% | $235.0M |
Table 8. Biotech startups that raised Series C: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 9 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 63 | 9% | $3.9B |
| 2025 | 63 | 9% | $3.4B |
| 2024 | 71 | 10% | $3.1B |
| 2023 | 44 | 6% | $1.5B |
| 2022 | 67 | 10% | $3.3B |
| 2021 | 81 | 12% | $5.8B |
Table 9. Biotech startups that raised Series C by year of the most recent round. Source: FundingWatcher. Data as of 9 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 0% |
| 2020 to 2022 | 24 | 3% |
| 2015 to 2019 | 241 | 35% |
| 2010 to 2014 | 174 | 25% |
| Before 2010 | 256 | 37% |
Table 10. Biotech startups that raised Series C by founding year. Source: FundingWatcher. Data as of 9 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 77 | 11% |
| 11 to 50 | 297 | 43% |
| 51 to 100 | 145 | 21% |
| 101 to 250 | 97 | 14% |
| 251 to 500 | 29 | 4% |
| 501 to 1,000 | 24 | 4% |
| 1,001 to 5,000 | 10 | 1% |
| 5,001 to 10,000 | 2 | 0% |
| 10,001 or more | 3 | 0% |
Table 11. Biotech startups that raised Series C by headcount. Source: FundingWatcher. Data as of 9 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C. On 9 November 2026 that is 700 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 700 rows: 74 have no round amount, 0 no city and 128 no website. The CSV has no description column.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups that raised Series C are on the list?
- 700, in the file dated 9 November 2026. 72 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 15 columns: name, website, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 700 rows, no account. Every investor and every startup, two files, cost $299.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 25 rows.
- How current is the data?
- The file is dated 9 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 25-row sample first. No account, no payment.